Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network.

Saved in:
Bibliographic Details
Title: Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network.
Authors: Hermine O; Department of Hematology, Hôpital Necker, Assistance Publique Hôpitaux de Paris, University Paris Descartes, Paris, France; INSERM U1163 and CNRS 8254, Imagine Institute, Université Sorbonne Paris Cité, Paris, France., Hoster E; Department of Internal Medicine III, Ludwig-Maximilians-University Hospital Munich, Munich, Germany; Institute of Medical Informatics, Biometry, and Epidemiology, Ludwig-Maximilians-University of Munich, Munich, Germany., Walewski J; Department of Lymphoid Malignancies, The Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland., Bosly A; Louvain Catholic University, Namur University Hospital, Namur, Belgium., Stilgenbauer S; Department of Internal Medicine, University of Ulm, Ulm, Germany., Thieblemont C; APHP-Saint-Louis Hospital, Hemato-oncology Department, Paris, France., Szymczyk M; Department of Lymphoid Malignancies, The Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland., Bouabdallah R; Department of Hematology, Institut Paoli-Calmettes, Marseille, France., Kneba M; Second Medical Department, University Hospital Schleswig-Holstein, Kiel, Germany., Hallek M; Department I of Internal Medicine, University of Cologne, Cologne, Germany., Salles G; Hospices Civils de Lyon, Université Claude Bernard, Centre Hospitalier Lyon-Sud, Pierre Bénite, France., Feugier P; Nancy University Hospital, Department of Hematology, Nancy, France., Ribrag V; Institut Gustave Roussy, Villejuif, France., Birkmann J; Department of Oncology, Paracelsus Medical University, Nuremberg, Germany., Forstpointner R; Department of Internal Medicine III, Ludwig-Maximilians-University Hospital Munich, Munich, Germany., Haioun C; Lymphoid Malignancies Unit, Hospital Henri Mondor, Créteil, France., Hänel M; Department of Internal Medicine III, Klinikum Chemnitz, Germany., Casasnovas RO; Hematologie Clinique, CHU Dijon, Dijon, France., Finke J; Department of Hematology and Oncology, University Hospital Freiburg, Freiburg, Germany., Peter N; Second Medical Department, Carl-Thiem-Klinikum Cottbus, Cottbus, Germany., Bouabdallah K; Department of Hematology and Cell Therapy, University Hospital of Bordeaux, Pessac, France., Sebban C; Department of Haematology, Centre Léon Bérard, Lyon, France., Fischer T; Department of Hematology and Oncology, University Hospital Magdeburg, Magdeburg, Germany., Dührsen U; Department of Hematology, University Hospital Essen, Essen, Germany., Metzner B; Department of Hematology and Oncology, University Hospital Oldenburg, Oldenburg, Germany., Maschmeyer G; Department of Hematology, Oncology and Palliative Medicine, Ernst-von-Bergmann-Hospital, Potsdam, Germany., Kanz L; Department of Medicine II, University of Tübingen, Tübingen, Germany., Schmidt C; Department of Internal Medicine III, Ludwig-Maximilians-University Hospital Munich, Munich, Germany., Delarue R; Department of Hematology, Hôpital Necker, Assistance Publique Hôpitaux de Paris, University Paris Descartes, Paris, France., Brousse N; Department of Pathology, Hôpital Necker, Assistance Publique Hôpitaux de Paris, University Paris Descartes, Paris, France., Klapper W; Department of Pathology, Hematopathology Section, and Lymph Node Registry, University of Kiel, Kiel, Germany., Macintyre E; Department of Biological Hematology, Hôpital Necker, Assistance Publique Hôpitaux de Paris, University Paris Descartes, Paris, France., Delfau-Larue MH; Department of Biological Hematology and Immunology, Henri-Mondor Hospital, Assistance Publique-Hôpitaux de Paris, INSERM U955, UPEC University, Creteil, France., Pott C; Second Medical Department, University Hospital Schleswig-Holstein, Kiel, Germany., Hiddemann W; Department of Internal Medicine III, Ludwig-Maximilians-University Hospital Munich, Munich, Germany., Unterhalt M; Department of Internal Medicine III, Ludwig-Maximilians-University Hospital Munich, Munich, Germany., Dreyling M; Department of Internal Medicine III, Ludwig-Maximilians-University Hospital Munich, Munich, Germany. Electronic address: Martin.Dreyling@med.uni-muenchen.de.
Corporate Authors: European Mantle Cell Lymphoma Network
Source: Lancet (London, England) [Lancet] 2016 Aug 06; Vol. 388 (10044), pp. 565-75. Date of Electronic Publication: 2016 Jun 14.
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1474-547X
DOI:10.1016/S0140-6736(16)00739-X